{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:02:10Z","timestamp":1793070130482,"version":"4.5.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizability and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study assesses the representation of race, ethnicity, and sex in interventional clinical trials of psilocybin and lysergic acid diethylamide (LSD) to evaluate disparities in participant diversity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of interventional trials registered on ClinicalTrials.gov up to 12 January 2025 that focused on classic psychedelics (psilocybin, psilocin, LSD, DMT, 5-MeO-DMT, and mescaline). Eligible trials were phases 2\u20134 and targeted psychiatric disorders or symptoms. Trials involving only healthy participants were excluded. Two reviewers extracted trial-level data independently; discrepancies were resolved by consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Nine eligible trials included eight with psilocybin and one with LSD. In the psilocybin trials (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009501), the age of participants ranged from 34.3 to 56.3 years; 47.7% were women. White participants accounted for 87.2%, while Black participants accounted for 3.0%, and Asian individuals accounted for 5.0%. Ethnicity was reported in 4 of 8 psilocybin trials (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009134), with 13.4% identifying as Hispanic or Latino. In four U.S.-only trials(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009139), participation-to-population ratios (PPRs) confirmed the underrepresentation of Black (PPR\u2009=\u20090.317) and Asian participants (PPR\u2009=\u20090.799). The LSD trial (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) included older adults (average age: 51.7\u2009years) who did not provide any information on race or origin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The limited diversity in psychedelic trials demonstrates the need for broader recruitment. Without better representation, the safety and efficacy of these therapies remain uncertain. Standardized reporting and targeted strategies are essential to ensure equity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251353250","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T11:52:12Z","timestamp":1752234732000},"page":"1014-1022","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-4652","authenticated-orcid":false,"given":"Damian","family":"Swieczkowski","sequence":"first","affiliation":[{"name":"Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland"},{"name":"Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Kwa\u015bny","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Ciurkowska","sequence":"additional","affiliation":[{"name":"Doctoral School of Social Sciences, University of Gda\u0144sk, Gdansk, Pomeranian Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pruc","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Szarpak","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland"},{"name":"Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA"},{"name":"Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland"},{"name":"Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2008.59.11.1264"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S128584"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-017-1400-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100410"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201500453"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000984"},{"issue":"1","key":"e_1_3_3_8_1","article-title":"Race, ethnicity, and other cultural background factors in trials of internet-based cognitive behavioral therapy for depression: Systematic review","volume":"26","author":"De Jes\u00fas-Romero R","year":"2024","unstructured":"De Jes\u00fas-Romero R, Holder-Dixon AR, Buss JF, et al. (2024) Race, ethnicity, and other cultural background factors in trials of internet-based cognitive behavioral therapy for depression: Systematic review. J of Med Internet Res 26(1): e50780.","journal-title":"J of Med Internet Res"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1625-6388"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"DeVito NJ Bacon S Goldacre B (2020) Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: A cohort study. Lancet 395(10221): 361\u2013369.","DOI":"10.1016\/S0140-6736(19)33220-9"},{"key":"e_1_3_3_11_1","unstructured":"U.S. Food and Drug Administration (2024a) Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products (Revision 1). U.S. Department of Health and Human Services. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical (accessed 20 May 2025)."},{"key":"e_1_3_3_12_1","unstructured":"U.S. Food and Drug Administration (2024b) Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. U.S. Department of Health and Human Services. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies (accessed 20 May 2025)."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/13634615221131465"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Fain KM Nelson JT Tse T et al. (2021) Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications. Contemp Clin Trials 101: 106237.","DOI":"10.1016\/j.cct.2020.106237"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/23337214241250108"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0051"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230682"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2019.015"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02172-2"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.2022254"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116359"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102711"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.05.007"},{"issue":"1","key":"e_1_3_3_25_1","first-page":"37","article-title":"The use of classic psychedelics for depressive and anxiety-spectrum disorders: A comprehensive review","volume":"45","author":"Kim V","year":"2025","unstructured":"Kim V, Wilson SM, Woesner ME, et al. (2025) The use of classic psychedelics for depressive and anxiety-spectrum disorders: A comprehensive review. J Clin Psychopharmacol 45(1): 37\u201345.","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00224499.2025.2479197"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.2307\/2626958"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111129"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852912001010"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2024.110194"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1824-6"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21070758"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae083"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.932605"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1391689"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Vi\u00f1a S. M. (2024). Minorities\u2019 Diminished Psychedelic Returns: Gender Perceived Stigma and Distress. Psychoactives 3(2) 303\u2013317. https:\/\/doi.org\/10.3390\/psychoactives3020019","DOI":"10.3390\/psychoactives3020019"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-024-02023-y"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220685"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2019.016"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.3.305"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-023-01160-5"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251353250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251353250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251353250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:19Z","timestamp":1777507939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251353250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/02698811251353250"],"URL":"https:\/\/doi.org\/10.1177\/02698811251353250","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}